Cris Lewis - Vice President, Biochemical and Cellular Pharmacology

Cris Lewis

Vice President, Biochemical and Cellular Pharmacology

"Genentech is an incredibly rich scientific environment, and it has been very exciting for our group to collaborate on projects across all therapeutic areas and platforms. Our lead-finding efforts continue to advance for both small molecule and biologics efforts, and our scientists enjoy having the opportunity to make diverse contributions throughout the lifetime of a project, from inception to clinical candidate nomination."
11
Years at Genentech
5
Awards & Honors

I joined Genentech in January 2006 to head up the Biochemical Pharmacology group in the Small Molecules Division. We put in tremendous effort to build our Small Molecule Discovery effort to be a world-class platform. We have now combined our Small Molecule in vitro biology group with the Therapeutic Antibody in vitro group, to form one large group that provides quantitative in vitro support for all of Genentech’s therapeutic programs. This allows our scientists to focus on the underlying science behind diseases, independent of the drug discovery platform. Moreover, it allows our scientists to broaden their drug discovery expertise if they desire.

The scientists in our Therapeutic Antibody group develop quantitative bioanalytical assays to support antibody screening and characterization, including mechanistic, pharmacokinetic, and pharmacodynamic assessments. Our Small Molecule division has responsibility for Compound Management, ultra-high-throughput screening, fragment screening, and all of the biochemical and cellular assays that provide quantitative structure-activity relationship data to guide Medicinal Chemistry efforts. In both groups, we collaborate closely with the scientists in the Disease Biology groups to ensure the testing cascades used by teams are of high quality and provide the necessary detailed mechanistic data to ensure that the right molecules move into the clinic. It has been a tremendously gratifying opportunity to help build this department, and I'm excited by some of the tremendous talent we have attracted to our organization.

Featured Publication

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Journal of Medicinal Chemistry. 2013; 56(11):4597-610.

Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D, Edgar KA, Friedman LS, Goldsmith R, Heald RA, Kolesnikov A, Lee L, Lewis C, Nannini M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Wallin JJ, Wang L, Wei B, Sampath D, Olivero AG.